Mallinckrodt PLC
MNK
Delayed Nyse - 12/14 10:02:27 pm
23.11USD
-3.14%

Mallinckrodt plc : to Report Earnings Results for Third Quarter of Fiscal 2017

Envoyer par e-mail
10/10/2017 | 10:57 pm

STAINES-UPON-THAMES, United Kingdom, Oct. 10, 2017 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, announced today it will report fiscal 2017 third quarter earnings results for the period of July 1, 2017, to Sept. 29, 2017, on Tuesday, Nov. 7, 2017.


A conference call for investors will begin at 8:30 a.m. Eastern Time. The call can be accessed in three ways:



-- At the Mallinckrodt website: http://www.mallinckrodt.com/investors.
-- By telephone: For both listen-only participants and those who wish to
take part in the question-and-answer portion of the call, the telephone
dial-in number in the U.S. is (877) 359-9508. For participants outside
the U.S., the dial-in number is (224) 357-2393. Callers will need to
provide the Conference ID of 98909272.
-- Through an audio replay: A replay of the call will be available
beginning at 11:30 a.m. Eastern Time on Tuesday, Nov. 7, 2017, and
ending at 11:59 p.m. Eastern Time on Tuesday, Nov. 21, 2017. Dial-in
numbers for U.S.-based participants are (855) 859-2056 or (800)
585-8367. Participants outside the U.S. should use the replay dial-in
number of (404) 537-3406. All callers will be required to provide the
Conference ID of 98909272.


ABOUT MALLINCKRODT

Mallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical products and therapies. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and hemostasis products. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing. To learn more about Mallinckrodt, visit www.mallinckrodt.com.


Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission (SEC) disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.


CONTACTS


Investor Relations

Coleman N. Lannum, CFA

Senior Vice President, Investor Strategy and IRO

314-654-6649

[email protected]


Daniel J. Speciale, CPA

Director, Investor Relations

314-654-3638

[email protected]


Media

Rhonda Sciarra

Senior Communications Manager

908-238-6765

[email protected]


Meredith Fischer

Chief Public Affairs Officer

314-654-3318

[email protected]



View original content with multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-plc-to-report-earnings-results-for-third-quarter-of-fiscal-2017-300534332.html


SOURCE Mallinckrodt plc


PRNewswire 2017
Envoyer par e-mail